Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Growth Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Vanguard Growth Index Fund ETF trades at $89. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VUG | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $90.29 |
52-Week Low | $0.48 | $70.00 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Vanguard Growth ETF (VUG) trades at $89.4, up 0.81% today, with a bullish technical signal driven by strong moving average support. Recent news highlights significant institutional buying interest, with multiple firms increasing stakes by over 500% in Q2 2026. The ETF focuses on large-cap growth stocks, offering broad exposure to innovative US companies.
Outlook remains positive given institutional accumulation and growth stock momentum, though an RSI of 95.06 on a 6-day basis indicates potential overbought conditions. Key risks include market volatility and sensitivity to interest rate changes, but long-term growth prospects appear solid based on historical performance and sector trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
